What is the purpose of this trial?
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
Ages: 18 years and older
Gender: Male only
Pfizer Inc., U.S. Pharmaceuticals Group
Dates: 04/03/2017 - 10/31/2018
Last Updated: 04/20/2017
Study HIC#: 1512016984